Septic Shock and Adjunctive Corticosteroids: ADRENAL's Hydrocortisone Alone or APROCCHSS's Combination
A single patient in refractory septic shock, whose escalating vasopressor requirement sits at the point where two major trials of adjunctive corticosteroids genuinely disagree.
Gerald P., a 66-year-old retired longshoreman, was admitted eighteen hours ago with a perforated diverticulum and has been in the ICU since his emergency laparotomy, now on norepinephrine at 0.45 mcg/kg/min and climbing despite adequate fluid resuscitation and source control. His wife has been at the bedside since the surgery ended, watching the pressor rate on the monitor the way she once watched cargo manifests come in low, she tells the nurse, for thirty years of his working life. His mean arterial pressure has held above 65 only with the last two upward titrations, and the team is now discussing whether adjunctive corticosteroids belong in his regimen at all, and if so, which regimen — a question two major 2018 trials answered differently enough that neither can simply be applied as the obvious default.
The ADRENAL trial, the larger of the two at over 3,800 patients enrolled across multiple countries, gave hydrocortisone alone and found faster shock reversal but no difference in 90-day mortality; its placebo arm's 90-day mortality of roughly 29%, set against APROCCHSS's roughly 49%, notably says that the two trials were not treating patients of remotely comparable severity, whatever else separates them. The same year, APROCCHSS gave hydrocortisone together with fludrocortisone in a French cohort skewing sicker, and found a real 90-day mortality reduction — 43.0% versus 49.1% in the placebo arm. The two trials were never run head-to-head against each other, so whether the mortality signal in APROCCHSS came from adding fludrocortisone specifically, or from enrolling a population closer to Gerald's own severity, is a genuinely open question neither trial alone can answer. His norepinephrine requirement — already approaching a dose most protocols treat as a trigger for adjunctive steroids — puts him closer to the sicker end of both trial populations than to a typical, more moderate vasopressor-dependent patient.
ICU bedside, hour 18, vasopressor still climbing
He's still climbing on norepinephrine despite source control and adequate fluids. APROCCHSS is the trial that actually showed a 90-day mortality benefit — 43.0% versus 49.1% — and it used hydrocortisone plus fludrocortisone in a population that looked a lot like where he's heading. I'd start both now rather than wait for him to get sicker before reaching for the regimen with a survival signal behind it.
I'd point out that ADRENAL — more than 3,800 patients, the larger and more internationally representative of the two — used hydrocortisone alone and found faster shock reversal but no mortality difference. Fludrocortisone was never tested against hydrocortisone alone in the same trial, so we don't actually know its specific incremental effect, especially since high-dose hydrocortisone itself carries real mineralocorticoid receptor activity that a synthetic glucocorticoid wouldn't.
I take the mortality number in APROCCHSS seriously — I'm not dismissing it — but a positive result in a sicker, more homogeneous single-country cohort isn't automatically the global answer over a larger, more heterogeneous trial that found no such difference.
I don't think these trials are actually disagreeing about the same question. They tested different regimens in populations that weren't identical, and neither directly rules out the other. What matters for tonight is which population Gerald resembles, and a rising norepinephrine requirement toward a dose most protocols already flag as a trigger for adjunctive steroids puts him closer to APROCCHSS's sicker cohort than to a routine case. I'd use hydrocortisone plus fludrocortisone for him specifically, without treating that as a rule for every septic shock patient who walks in tomorrow at a lower pressor dose.
Agreed: start hydrocortisone plus fludrocortisone per the APROCCHSS regimen tonight, given his escalating vasopressor requirement, with vasopressor titration continuing independently.
Not agreed: whether this should become the unit's default regimen for any patient meeting the same pressor-dose trigger, or whether the matching-by-severity approach should be applied case by case as tonight. The intensivist would prefer a fixed unit protocol built around the APROCCHSS threshold; the pharmacologist is wary of converting a single patient's resemblance argument into a standing rule without more direct comparative evidence.